Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.Oxford BioMedica’s products use genes as the mediators of a therapeutic effect and/or immune response. The Company’s gene therapy products deliver therapeutic molecules in vivo whilst its gene-based immunotherapy products deliver genes that recruit the patient’s immune system to mediate a therapeutic effect. The genes are delivered by the Company’s highly engineered viral systems.
Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes two candidates in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. A Phase III trial in renal cancer with TroVax, the lead cancer immunotherapy candidate, is planned for 2006. In neurotherapy, the Company’s lead product is a gene therapy for Parkinson’s disease, which is expected to enter clinical development in 2006, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.
| Contact Details: |
| 11622 El Camino Real #100 |
| San Diego |
| California |
| 92130 |
| United States of America |
| Tel: | 1 858 677 6500 |
| Fax: | 1 858 677 6505 |
| Email: | enquiries@biomedica-usa.com |
| WWW: | www.oxfordbiomedica.co.uk/
|
|
Loading...
|
Press Releases on BioMedica Inc.:
|
 |
| Oxford Biomedica Announces Appointment Of Chief Medical Officer |
1st September, 2005 |
Oxford Biomedica |
Oxford
Biomedica Announces Appointment Of Chief Medical Officer
Oxford, UK: 7 September 2005
–
Oxford BioMedica
(LSE:OXB.L), the
|
| OXFORD BIOMEDICA SUCCESSFULLY COMPLETES STAGE ONE OF THE PHASE II TRIAL
|
1st August, 2005 |
Oxford Biomedica |
OXFORD
BIOMEDICA SUCCESSFULLY COMPLETES STAGE ONE OF THE PHASE II TRIAL WITH METXIA
IN PANCREATIC CANCER
Oxford,
UK: 1 August 2005
|
| Oxford Biomedica Is Granted Key Lentivector® Patents In China |
1st July, 2005 |
Oxford Biomedica |
Oxford Biomedica Is Granted Key
Lentivector® Patents In China
Oxford, UK: 4 July 2005 – Oxford
BioMedica (LSE: OXB), the leading gene therapy company, announced today that the
Patent
|
| Oxford Biomedica Presents Encouraging Innurex Preclinical Efficacy Data
|
1st June, 2005 |
Oxford Biomedica |
Oxford Biomedica Presents
Encouraging Innurex Preclinical Efficacy Data In Spinal Cord Injury
- Presentation at
the 8th Annual Meeting of the American Society of Gene Therapy, 1-5
|
| Oxford Biomedica Signs Lentivector® Licensing Agreement With Pfizer |
1st June, 2005 |
Oxford Biomedica |
Oxford Biomedica Signs
Lentivector® Licensing Agreement With Pfizer
Oxford, UK: 6 June 2005
– Oxford
BioMedica (LSE: OXB), the leading gene therapy company, announced today that it
has
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 373 times since April 2007, the link to the organisation's website has been followed 57 times
Recent Search Terms used to find this page: Biomedica Inc. | .
Search for more companies in San Diego
Search for more companies in California
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
BioMedica Inc.
